We are live on
!
Find out more
PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$5.34B
1-Year Est. Return
380.18%
This Fund
S&P 500
This Quarter
Est. Return
+40.65%
1 Year Est. Return
+380.18%
3 Year Est. Return
+803.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.34B
AUM Growth
+$446M
(+9.1%)
Cap. Flow
-$643M
Cap. Flow
% of AUM
-12.03%
Top 10 Holdings %
Top 10 Hldgs %
75.21%
Holding
42
New
7
Increased
12
Reduced
7
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$145M |
| 2 |
Spyre Therapeutics
SYRE
|
+$137M |
| 3 |
Genmab
GMAB
|
+$137M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$98.3M |
| 5 |
MBX
MBX Biosciences
MBX
|
+$87.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACLX
Arcellx
ACLX
|
+$663M |
| 2 |
Vaxcyte
PCVX
|
+$145M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$142M |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$117M |
| 5 |
Cytokinetics
CYTK
|
+$97.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lexeo Therapeutics
LXEO
$401M
| $19.4M | 0.36% |
4,175,382
-2,008,752
| -32% | -$10.9M |
|
27
Editas Medicine
EDIT
$496M
| $18.1M | 0.34% |
+5,586,625
| New | +$16.3M |
|
|
IVA
28
Inventiva
IVA
$1.13B
| $15.1M | 0.28% |
4,000,000
| – | – |
|
|
ABVX
29
Abivax
ABVX
$10B
| – | – |
-772,473
| Closed | -$86M |
|
|
ACLX
30
DELISTED
Arcellx
ACLX
| – | – |
-5,774,016
| Closed | -$663M |
|
|
CNTA
31
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-3,574,048
| Closed | -$142M |
|
|
32
Cytokinetics
CYTK
$10.1B
| – | – |
-1,480,857
| Closed | -$97.6M |
|
33
Structure Therapeutics
GPCR
$3.38B
| – | – |
-545,287
| Closed | -$26.3M |
|
34
Mirum Pharmaceuticals
MIRM
$6.15B
| – | – |
-625,000
| Closed | -$57.7M |
|
35
Oric Pharmaceuticals
ORIC
$1.33B
| – | – |
-1,701,217
| Closed | -$21.6M |
|
36
Scholar Rock
SRRK
$6.74B
| – | – |
-1,226,080
| Closed | -$60.3M |
|
|
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-2,216,499
| Closed | -$117M |
|
38
UroGen Pharma
URGN
$2.16B
| – | – |
-1,703,949
| Closed | -$30.6M |
|
|
BBOT
39
BridgeBio Oncology
BBOT
$720M
| – | – |
-868,213
| Closed | -$7.77M |
|
|
MAZE
40
Maze Therapeutics
MAZE
$1.46B
| – | – |
-2,744,399
| Closed | -$81.9M |
|
|
KLRS
41
Kalaris Therapeutics
KLRS
$92.8M
| – | – |
-700,000
| Closed | -$4.04M |
|
|
MANE
42
Veradermics Inc
MANE
$4.12B
| – | – |
-525,000
| Closed | -$33.2M |
|
Similar funds
FFB
WTC
IFG
CAU
CCWM
NL
SFI
Paradigm Biocapital Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Paradigm Biocapital Advisors held 42 positions worth $5.34B, up 9.1% from $4.89B the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Paradigm Biocapital Advisors withdrew a net $643M in Q2 2026, closing 14 positions and reducing 7 holdings. Its most notable exit was Arcellx, an estimated $663M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Paradigm Biocapital Advisors opened a new position in Alnylam Pharmaceuticals worth $144M.
- Paradigm Biocapital Advisors's largest Q2 2026 buy was Alnylam Pharmaceuticals: 480,000 shares worth $144M.
- Paradigm Biocapital Advisors added most to Spyre Therapeutics in Q2 2026, an estimated $137M increase.
- Paradigm Biocapital Advisors's biggest Q2 2026 reduction was Vaxcyte, cutting an estimated $145M.
- Paradigm Biocapital Advisors fully exited Arcellx in Q2 2026, selling an estimated $663M.
- Paradigm Biocapital Advisors's ten largest holdings make up 75% of its $5.34B portfolio in Q2 2026.
- Paradigm Biocapital Advisors opened 7 new positions and closed 14 in Q2 2026.
- Paradigm Biocapital Advisors's portfolio value rose 9.1% quarter-over-quarter to $5.34B.
Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.